Vicore Pharma Holding AB ADR (VCRE)
NASDAQ: VCREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
VCRE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $243.90M
- EPS (TTM)
- -$1.98
- Dividend yield
- None
- 52-week range
- 8.39 – 17.80
- Day range
- 8.39 – 8.80
- Volume / Avg
- 32.05K / 15.99K
- Beta
- —
- Shares outstanding
- 28.16M
52-week range
VCRE stock today
On Oct 7, VCRE ended the session at $8.66, shedding $0.2438 (2.74%), versus the S&P 500's 0.22% decline. Volume was 2.0x the average at 32.05K shares, a sign of unusually heavy trading. At this level, VCRE sits near the bottom of its 52-week range of $8.39 to $17.80: 51.3% below the high, set on Jul 7, 2026 and 3.2% above the low.
Vicore Pharma AB has posted a net loss over the last twelve months (EPS of -$1.98), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Vicore Pharma AB
Company profileVicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ahmed S. Mousa J.D.
- Headquarters
- Stockholm
- Employees
- 46
- Website
- vicorepharma.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$33.16+282.91%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Vicore Pharma AB peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INOInovio Pharmaceuticals Inc. | 1.16 | +2.21% | $119.42M | vs VCRE |
| COYACoya Therapeutics Inc. | 4.91 | +1.24% | $115.18M | vs VCRE |
| UNCYUnicycive Therapeutics Inc. | 4.18 | -1.18% | $114.50M | vs VCRE |
| RANIRani Therapeutics Holdings Inc. Class A | 0.8121 | -2.02% | $114.12M | vs VCRE |
| GNLXGenelux Corporation | 2.52 | -0.79% | $114.02M | vs VCRE |
| PMVPPMV Pharmaceuticals Inc. | 1.50 | -6.83% | $113.27M | vs VCRE |
| AARDAardvark Therapeutics Inc. | 4.96 | -1.59% | $108.55M | vs VCRE |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 5.49 | -5.02% | $106.18M | vs VCRE |
Indexes, lists and sector
Vicore Pharma AB stock FAQ
What is Vicore Pharma AB's stock price today?
VCRE last traded at $8.66 as of Oct 7, 4:00 PM EDT, down 2.74% on the day. Prices are delayed at least 15 minutes.
Who is Vicore Pharma AB's CEO?
Mr. Ahmed S. Mousa J.D. is the chief executive officer of Vicore Pharma Holding AB ADR, which has about 46 employees.
What is the VCRE 52-week high?
The 52-week high for VCRE is $17.80 and the 52-week low is $8.39. The stock is currently 51.3% below its high.